Bill Ackman (Trades, Portfolio) added two new positions to his portfolio, according to GrurFocus Real Time Picks. The new additions bring his number of stocks to a total of eight and valued around $14.97 billion. His portfolio's quarter-over-quarter turnover is 29%.
Ackman purchased 19,473,933 shares of Valeant Pharmaceuticals International Inc (VRX, Financial) at an average price of $177.40 a share.
Valeant is a multinational, specialty pharmaceutical and medical device company that develops, markets and manufactures numerous branded or generic pharmaceuticals, over-the-counter products and media devices.
The Peter Lynch earnings line is currently at $42.10 and the stock is trading at $225.86, which indicates that it may be currently overvalued.
EBITDA per share for the trailing twelve months as of March 2015 was $11.73 and its growth rate was 144.70% for the past year.
1,348,358 shares of Actavis PLC (ACT, Financial) were purchased at an average price of $285.10 a share.
Actavis is an integrated pharmaceutical company that develops, manufactures, markets, sales and distributes generic and branded over-the-counter pharmaceutical products. The company was incorporated in 2013. The stock is currently trading at $295.76 a share.
The company's current ratio is at a comfortable 1.44, which indicates that it has good short-term financial strength.
For a complete list of positions in Ackman's portfolio, click here.